C-RQTQMogling Bio
Cdc42 inhibition, CASIN, stem cell rejuvenation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RQTQ
C-RQTQC-RQTQCdc42 inhibition, CASIN, stem cell rejuvenation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mogling Bio states that aging in blood-forming stem cells can be pharmacologically reversed or mitigated. The company presents the view that old hematopoietic stem cells become internally disorganized with age, that this dysfunction impairs blood and immune cell production and contributes to blood disease risk, and that targeting the molecular drivers of this aging state could rejuvenate stem cell function.
SourceMogling Bio states that aging disrupts the internal organization and function of blood-forming hematopoietic stem cells, reducing blood and immune cell production and contributing to blood diseases. The company argues that elevated Cdc42 activity is a driver of this stem-cell aging and that pharmacologically inhibiting Cdc42 can re-order and rejuvenate old hematopoietic stem cells, potentially improving immune function and reducing aging-associated disease.
SourceMogling Bio states that aging disrupts the internal organization and function of hematopoietic stem cells (HSCs), impairing blood and immune cell production and contributing to diseases such as leukemia. The company’s stated belief is that elevated Cdc42 activity is a causal driver of HSC aging, and that pharmacologically inhibiting this elevated activity can re-order, rejuvenate, and restore old HSC function, potentially improving immune decline and ameliorating aging-associated diseases including multiple myeloma and myelodysplastic syndromes.
SourceMogling Bio states that aging in blood-forming stem cells is driven in part by disorganization of their internal structure and elevated activity of the small RhoGTPase Cdc42, which impairs blood and immune cell production and contributes to age-related blood diseases. The company says that reducing elevated Cdc42 activity can reorder and rejuvenate old hematopoietic stem cells, extend lifespan in mice, and potentially restore immune function while ameliorating aging-associated diseases such as multiple myeloma and myelodysplastic syndromes.
Source